The latest journal from EASL, JHEP Reports is fully open access.Our goal is to become an essential channel for innovation in hepatology by publishing outstanding basic, translational and clinical studies.
A revision is proposed for current WHO guidelines for chronic hepatitis B (CHB) as they fail to detect half of the patients in need of treatment in Ethiopia
In a new study in the Journal of Hepatology, researchers report favorable 10-year survival rates for patients with HBV and/or HCV treated with antiviral agents and advise that antiviral therapy should be systematically offered to all HBV and HCV patients in line with international recommendations.
It is estimated that 2 billion people are infected with hepatitis B virus (HBV) globally, with 686,000 people dying from complications of the disease each year.
Hepatic encephalopathy (HE) is a frequent complication in patients with chronic liver disease. HE is a complication of cirrhosis that is associated with psychomotor slowing and an increased risk of accidents at home, at work, or while driving a car…
Before the advent of antiretroviral drugs, the prognosis for patients with AIDS was extremely poor. However, new antiretroviral treatments have revolutionised care for patients with HIV/AIDS, making lifelong viral suppression possible and improving life expectancy to near normal in patients…
Liver cancer is a leading cause of cancer death, with hepatocellular carcinoma (HCC) accounting for 85–90% of all primary liver cancers. In a recent issue of Journal of Hepatology, Dr Baumeister et al. showed that higher total physical activity was…
Study finds fatty liver disease is less likely to occur in mothers who breastfeed for more than six months. Researchers at UC San Diego School of Medicine and Kaiser Permanente have discovered that mothers who breastfed a child or children…
Geneva, Switzerland, 20 September 2018 - The EASL Nonalcoholic Fatty Liver Disease (NAFLD) Summit commenced today at the Starling Hotel Conference Centre in Geneva, Switzerland, attended by over 300 basic and clinical researchers, industry, and renowned specialists from around the world.
While the prevalence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) continues to rise, with both conditions increasingly recognised in primary care and specialist practice, quantifying future disease burden has always been challenging. This is largely due to…